Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01247363 | A Study of LY2608204 in Patients With Type 2 Diabetes | PHASE1 | COMPLETED | 20 | — | — | Nov 1, 2010 | Mar 1, 2011 | Nov 16, 2018 | 2 | United States, Singapore |
Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.
| Arm | Type | Description |
|---|---|---|
| LY2608204 | EXPERIMENTAL | Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment. |
| Name | Type | Description |
|---|---|---|
| LY2608204 | DRUG | Administered orally. |
Inclusion Criteria: * Patients diagnosed with Type 2 diabetes mellitus (T2DM) who are currently treated with diet/lifestyle measures alone or in combination with anti-diabetic agents, including insulins * Have fasting blood glucose (FBG) greater than or equal to 160 milligram/deciliter (mg/dL), wit...